目的 探讨苓桂咳喘宁胶囊联合茶碱缓释片治疗哮喘急性发作的临床效果。方法 选取2021年1月—2021年12月亳州市人民医院收治的100例哮喘急性发作患者，按随机数字表法分为对照组与治疗组，每组各50例。对照组口服茶碱缓释片，1片/次，2次/d。治疗组在对照组基础上口服苓桂咳喘宁胶囊，5粒/次，3次/d。两组均连续治疗14 d。观察两组的临床疗效，比较两组治疗前后肺通气功能指标、哮喘生命质量问卷（AQLQ）评分及相关炎症指标水平。结果 治疗后，治疗组总有效率是96.0%，较对照组的84.0%显著提高（P<0.05）。治疗后，治疗组咳嗽、气促、胸闷、喘息和肺部哮鸣音等典型表现的消失时间较对照组均显著缩短（P<0.05）。治疗后，两组第1秒用力呼气容积（FEV₁）占预计值%显著高于治疗前，而呼气峰流速（PEF）昼夜变异率低于治疗前（P<0.05）；但均以治疗组的改善更显著（P<0.05）。治疗后，两组AQLQ中症状、情感功能、活动受限、环境刺激评分及其总分均显著高于治疗前（P<0.05）；但治疗后，治疗组AQLQ中各能区评分及其总分的提高作用较对照组更显著（P<0.05）。与治疗前相比，两组患者治疗后外周血嗜酸性粒细胞（EOS）计数、呼出气一氧化氮（FeNO）、白细胞介素（IL）-6水平均显著下降（P<0.05）；且治疗组患者外周血EOS计数、FeNO及血清IL-6水平低于对照组（P<0.05）。结论 苓桂咳喘宁胶囊与茶碱缓释片联合治疗哮喘急性发作的效果确切，是缓解患者哮喘症状、改善气流受限及提高生活质量的安全有效方案，并能进一步缓解患者体内炎症反应，有利于控制病情。

Objective To investigate the clinical effect of Linggui Kechuanning Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attack. Methods A total of 100 patients with acute asthma attack admitted to Bozhou People's Hospital from January 2021 to December 2021 were selected and divided into control group and treatment group according to random number table method, with 50 cases in each group. Patients in the control group were po administered with Theophylline Sustained-release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Linggui Kechuanning Capsules on the basis of the control group, 5 grains/time, three times daily. Both groups were treated for 14 d. The clinical efficacy of the two groups were observed, and the levels of pulmonary ventilation function indexes, asthma quality of life questionnaire (AQLQ) score and related inflammatory indexes were compared between the two groups before and after treatment. Results After treatment, the total effective rate of the treatment group was 96.0%, significantly higher than that of the control group (84.0%) (P < 0.05). After treatment, the disappearance time of typical symptoms such as cough, shortness of breath, chest tightness, wheezing and pulmonary wheezing in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the proportion of FEV1% in both groups was significantly higher than before treatment, while the diurnal variation rate of PEF was lower than before treatment (P < 0.05). However, the improvement in treatment group was more significant (P< 0.05). After treatment, AQLQ symptoms, affective function, activity limitation, environmental stimulus score and total score in two groups were significantly higher than before treatment (P < 0.05). However, after treatment, AQLQ scores and total scores in the treatment group were more significant than those in the control group (P < 0.05). Compared with before treatment, eosinophil (EOS) count, nitric oxide (FeNO) and interleukin (IL-6) levels in peripheral blood of two groups were significantly decreased after treatment (P < 0.05). After treatment, the treatment group had more significant effect on the decrease of EOS count in peripheral blood, FeNO and serum IL-6 levels than the control group (P < 0.05). Conclusion Linggui Kechuanning Capsules combined with Theophylline Sustained-release Tablets has accurate effect in treatment of acute asthma attack, and is a safe and effective solution to relieve asthma symptoms, improve airflow limitation and improve life quality, and can further alleviate the inflammatory response in patients, which helps to control the disease.

R974

亳州市科技局科研项目（1604a0802091）